The creation of new antitumor therapeutics, especially new chemotherapy and targeted therapy, is a perennial subject that keeps up with the times. Owing to its high morbidity and longevity, cancer is the second major cause of death. Cytotoxic medications have had a lot of effectiveness in treating tumors, but their cytotoxic effects can also damage healthy cells in the body, causing severe side effects. Targeted treatment varies from conventional chemotherapy in that it inhibits certain genes or proteins that distinguish cancer cells from normal cells. These genes or proteins are often involved in cancer development, proliferation, and metastasis. Cancers such as lung, colorectal, breast, lymphoma, and leukaemia benefit from selective cancer treatments because they work on subtle molecular modifications that are special to each cancer. As a result, Small Molecule targeted therapy offers a more precise treatment choice, with patients receiving medications that target particular molecular targets linked to cancer.
- Higher Response Rate
- Prevalence of Chronic Cancer Cases
- Rising Healthcare Infrastructure
- Expensive Procedures
- Side Effects Such as Hair Loss & Fatigue
- Lack of Trained Professionals
The key Players profiled in the report are Abbott Laboratories (United States), GlaxoSmithKline plc (United Kingdom), Pfizer Inc. (United States), Mylan Pharmaceuticals (United States), OncoGenex Pharmaceuticals (United States), Cytokinetics Inc. (United States), Hospira Inc. (United States), Boehringer Ingelheim GmbH (Germany) and Bayer HealthCare AG (Germany).